Literature DB >> 9165695

Therapy and prevention of gastric ulcer.

C B Lamers1, I Biemond, A A Masclee, R A Veenendaal.   

Abstract

After establishing the benign nature of a gastric ulcer, the treatment is primarily medical. This medical therapy is aimed to alleviate symptoms, to heal the ulcer and to prevent relapses. Based on the history of non-steroidal anti-inflammatory drugs (NSAIDs) and the Helicobacter pylori-status, gastric ulcer patients can be divided into four categories (1) H. pylori positive plus NSAID-use, (2) H. pylori positive without NSAID use, (3) NSAID use with negative H. pylori-status, (4) Negative H. pylori-status and no NSAID use. Patients taking NSAIDs should stop this therapy if possible. Patients with gastric H. pylori infection should be treated by a regimen of a proton pump inhibitor with at least two appropriate antibiotics. This treatment will result in early alleviation of symptoms, rapid healing of the ulcer and prophylaxis of ulcer relapse. In patients with gastric ulcer who cannot stop NSAIDs, maintenance therapy with prostaglandins or potent antisecretory drugs should be considered. The few patients with gastric ulcer who do not take NSAIDs and do not have gastric H. pylori infection should be treated by antisecretory drugs, and they should be carefully followed endoscopically to exclude malignant (carcinoma, lymphoma) or non-peptic (Crohn's disease) disease. All patients with gastric ulcer should be re-endoscoped to verify complete ulcer healing. Surgery may be considered in gastric ulcer patients with complications, in those with severe dysplasia of the gastric mucosa, and in those who are not able or willing to take the medication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9165695      PMCID: PMC2589011     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  27 in total

Review 1.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Effects of Helicobacter pylori infection on healing and recurrence of gastric ulcers.

Authors:  M Tatsuta; H Iishi; Y Yokota
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

3.  Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.

Authors:  J J Sung; S C Chung; T K Ling; M Y Yung; V K Leung; E K Ng; M K Li; A F Cheng; A K Li
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

4.  The natural course of peptic ulcer disease and its predictors.

Authors:  H Petersen; P Kristensen; T Johannessen; P M Kleveland; J H Dybdahl; H Myrvold
Journal:  Scand J Gastroenterol       Date:  1995-01       Impact factor: 2.423

5.  Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial.

Authors:  S L Elliott; N D Yeomans; R R Buchanan; R A Smallwood
Journal:  Scand J Rheumatol       Date:  1994       Impact factor: 3.641

6.  Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group.

Authors:  K Seppälä; P Pikkarainen; P Sipponen; E Kivilaakso; M H Gormsen
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

7.  The effect of cisapride and ranitidine as monotherapies and in combination in the treatment of uncomplicated gastric ulceration.

Authors:  A Stubberöd; H Glise; B Hallerbäck; J H Solhaug
Journal:  Scand J Gastroenterol       Date:  1995-02       Impact factor: 2.423

8.  Risk of recurrence of gastric ulcer, chronic gastritis, and grade of Helicobacter pylori colonization. A long-term follow-up study of 25 patients.

Authors:  H I Maaroos; M Kekki; T Vorobjova; V Salupere; P Sipponen
Journal:  Scand J Gastroenterol       Date:  1994-06       Impact factor: 2.423

9.  Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.

Authors:  D L Avner; R Movva; K J Nelson; M McFarland; W Berry; W Erfling
Journal:  Am J Gastroenterol       Date:  1995-08       Impact factor: 10.864

10.  Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens.

Authors:  J B Raskin; R H White; J E Jackson; A L Weaver; E A Tindall; R B Lies; D S Stanton
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

View more
  1 in total

1.  Gastroprotective effect of araloside A on ethanol- and aspirin-induced gastric ulcer in mice: involvement of H+/K+-ATPase and mitochondrial-mediated signaling pathway.

Authors:  Haibo He; Xiaomei Li; Haili Yu; Shu Zhu; Yumin He; Katsuko Komatsu; Dongyan Guo; Xiaoqin Li; Junzhi Wang; Huajun Luo; Daoxiang Xu; Kun Zou
Journal:  J Nat Med       Date:  2018-12-06       Impact factor: 2.343

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.